Subscribe
Komsan Loonprom / Shutterstock.com
11 September 2025NewsAmericasMuireann Bolger

Sandoz eyes US biosimilar launch as Regeneron settles

Deal resolves just one case in Regeneron’s roll-call of actions against competitors looking to launch versions of a $6bn-a-year blockbuster eye-disease treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Regeneron hits Amgen over its blockbuster eye disease treatment
19 June 2025   The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.
Americas
Regeneron edges closer to Eylea market exclusivity amid biosimilar threats
6 March 2025   New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.
Americas
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
13 February 2025   The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.


Editor's picks

IP agencies vital to pharma and biotech grind to a halt
Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025

Editor's picks

Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Killing the golden goose of US drug innovation (Part I): Follow the money
10 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025

More features

IP agencies vital to pharma and biotech grind to a halt
USPTO trims workforce amid govt shutdown crisis
How impactful is the new USPTO director’s S101 decision?
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
Philips wins unprecedented trade secret sanctions against Chinese defendants
Womble Bond Dickinson partners jump to rival firm
EPO ruling clarifies appeal rights, blocking third-party intervention
Biotech sues AstraZeneca and Cellectis over mRNA patents